Answers are grounded in this paper and cite their sources.
This consensus statement from the Japanese Respiratory Society summarizes updated recommendations for the diagnosis and treatment of drug-induced lung injury (DLI). DLI includes respiratory disorders caused by prescription drugs, over-the-counter medicines, herbal agents, and supplements. Clinical manifestations range widely from mild and reversible conditions to severe and life-threatening disease. Among these, diffuse alveolar damage (DAD) is particularly important because it is associated with severe respiratory failure, poor treatment response, fibrosis, and high mortality. An accurate diagnosis requires careful exclusion of other causes, especially respiratory infections, heart failure, and progression of the underlying disease. Chest computed tomography imaging has a central role in diagnosis and classification, particularly for distinguishing DAD from non-DAD patterns such as organizing pneumonia, hypersensitivity pneumonitis, and nonspecific interstitial pneumonia. Biomarkers including Krebs von den Lungen-6, surfactant protein-A, and surfactant protein-D may assist in disease evaluation and monitoring. Major causative agents include anticancer drugs, immune checkpoint inhibitors, molecular target drugs, antimicrobial agents, and antirheumatic drugs. Risk factors include older age, pre-existing interstitial lung disease, smoking history, impaired respiratory function, and combination chemotherapy. The cornerstone of management is prompt discontinuation of the suspected drug, followed by glucocorticoid therapy according to disease severity and appropriate respiratory support. Early recognition, multidisciplinary evaluation, and close monitoring are essential for improving patient outcomes.
No takes yet. Share an insight, caveat, or question.
Ushiki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: